In-111 rosopatamab tetraxetan

N/A

Report date: 2025/11/25 15:56:58

Base Information

Drug NameIn-111 rosopatamab tetraxetan

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Nuclides > Indium > 111In +[4]

Mechanisms of ActionPositron-emission tomography enhancersProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesConvergent Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesConvergent Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A